Latest filings (excl ownership)
D
$12.42 mm in options / securities to be acquired, 3 investors
25 Apr 24
8-K
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
18 Apr 24
EFFECT
Notice of effectiveness
18 Apr 24
424B4
Prospectus supplement with pricing info
17 Apr 24
S-1/A
IPO registration (amended)
16 Apr 24
8-K
Longeveron Announces Pricing of $5.25 Million Public Offering
11 Apr 24
424B3
Prospectus supplement
10 Apr 24
424B4
Prospectus supplement with pricing info
10 Apr 24
EFFECT
Notice of effectiveness
9 Apr 24
FWP
Free writing prospectus
8 Apr 24
S-1/A
IPO registration (amended)
5 Apr 24
S-1/A
IPO registration (amended)
3 Apr 24
S-1
IPO registration
19 Mar 24
8-K
Longeveron Announces 1-for-10 Reverse Stock Split
19 Mar 24
10-K/A
2023 FY
Annual report (amended)
11 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
22 Feb 24
DEF 14A
Definitive proxy
5 Feb 24
S-1
IPO registration
29 Jan 24
PRE 14A
Preliminary proxy
25 Jan 24
D
$2.57 mm in options / securities to be acquired, 1 investor
8 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
28 Dec 23
8-K
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
22 Dec 23
424B5
Prospectus supplement for primary offering
22 Dec 23
424B3
Prospectus supplement
6 Dec 23
EFFECT
Notice of effectiveness
22 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
S-1
IPO registration
15 Nov 23
DEFA14A
Additional proxy soliciting materials
13 Nov 23
DEF 14A
Definitive proxy
13 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
PRE 14A
Preliminary proxy
2 Nov 23
D
$8.35 mm in options / securities to be acquired, 1 investor
24 Oct 23
8-K
Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
13 Oct 23
424B5
Prospectus supplement for primary offering
13 Oct 23
8-K
Longeveron Announces Positive Top-Line Results for Lomecel-BTM in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
5 Oct 23
8-K
Other Events
25 Sep 23
25-NSE
Exchange delisting
21 Sep 23
Latest ownership filings
SC 13G
INTRACOASTAL CAPITAL, LLC
17 Apr 24
SC 13D/A
Hare Joshua
15 Apr 24
4
Joshua Hare
12 Apr 24
4
Mohamed Wa'el Ahmed Hashad
12 Apr 24
4
Rock Soffer
12 Apr 24
4
Mohamed Wa'el Ahmed Hashad
20 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Mohamed Wa'el Ahmed Hashad
2 Feb 24
4
Lisa Locklear
25 Jan 24
4
Mohamed Wa'el Ahmed Hashad
25 Jan 24
4
Paul T Lehr
25 Jan 24
4
Nataliya Agafonova
25 Jan 24
4
Cathy Ross
11 Jan 24
4
Khoso Baluch
2 Jan 24
4
JEFFREY PFEFFER
29 Dec 23
4
DOUGLAS W LOSORDO
26 Dec 23
4
Joshua Hare
26 Dec 23
4
Rock Soffer
26 Dec 23
4
Ursula Ungaro
26 Dec 23
4
Cathy Ross
26 Dec 23
4
Neil E Hare
26 Dec 23
4
Khoso Baluch
26 Dec 23
4
JEFFREY PFEFFER
26 Dec 23
SC 13D/A
Hare Joshua
18 Dec 23
4
Paul T Lehr
4 Oct 23
4
Lisa Locklear
4 Oct 23
4
Nataliya Agafonova
4 Oct 23
4
Joshua Hare
22 Sep 23
4
Paul T Lehr
21 Sep 23
4
Joshua Hare
14 Sep 23
4
Lisa Locklear
13 Sep 23
4
Mohamed Wa'el Ahmed Hashad
13 Sep 23
4
Joshua Hare
13 Sep 23
4
Rock Soffer
12 Sep 23
4
Mohamed Wa'el Ahmed Hashad
6 Sep 23
4
Paul T Lehr
22 Aug 23
4
Nataliya Agafonova
22 Aug 23
4
Mohamed Wa'el Ahmed Hashad
22 Aug 23
4
Lisa Locklear
2 Aug 23
3
Lisa Locklear
2 Aug 23